Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acute Kidney Injury | 55 | 2024 | 1972 | 9.460 |
Why?
|
Fibroblast Growth Factors | 14 | 2020 | 879 | 3.280 |
Why?
|
Critical Illness | 30 | 2023 | 2670 | 2.310 |
Why?
|
Renal Replacement Therapy | 12 | 2023 | 257 | 2.040 |
Why?
|
Cardiac Surgical Procedures | 12 | 2021 | 3537 | 1.600 |
Why?
|
Intensive Care Units | 23 | 2022 | 3679 | 1.410 |
Why?
|
Iron | 7 | 2023 | 1774 | 1.370 |
Why?
|
Cisplatin | 4 | 2024 | 1662 | 1.010 |
Why?
|
Kidney | 15 | 2024 | 7186 | 0.990 |
Why?
|
Platelet Factor 4 | 1 | 2023 | 129 | 0.910 |
Why?
|
Anemia, Hemolytic, Autoimmune | 3 | 2021 | 142 | 0.900 |
Why?
|
Kidney Calculi | 3 | 2013 | 465 | 0.900 |
Why?
|
Calcitriol | 2 | 2014 | 298 | 0.890 |
Why?
|
Vitamins | 4 | 2022 | 1622 | 0.890 |
Why?
|
Hospital Mortality | 21 | 2022 | 5317 | 0.870 |
Why?
|
Nephritis, Interstitial | 3 | 2022 | 156 | 0.870 |
Why?
|
Vitamin D | 10 | 2021 | 3223 | 0.820 |
Why?
|
Ritonavir | 1 | 2023 | 322 | 0.780 |
Why?
|
Diphenhydramine | 1 | 2021 | 63 | 0.770 |
Why?
|
Dialysis Solutions | 1 | 2020 | 39 | 0.720 |
Why?
|
Renal Insufficiency, Chronic | 8 | 2023 | 2208 | 0.720 |
Why?
|
Hemoglobins | 4 | 2019 | 1534 | 0.710 |
Why?
|
Critical Care | 7 | 2021 | 2647 | 0.700 |
Why?
|
Cardiopulmonary Bypass | 4 | 2020 | 1066 | 0.690 |
Why?
|
Peritoneal Dialysis | 1 | 2020 | 146 | 0.680 |
Why?
|
Hyperkalemia | 2 | 2023 | 218 | 0.670 |
Why?
|
Iron Chelating Agents | 1 | 2019 | 139 | 0.650 |
Why?
|
Thrombotic Microangiopathies | 2 | 2018 | 132 | 0.630 |
Why?
|
ABO Blood-Group System | 1 | 2020 | 367 | 0.620 |
Why?
|
Sepsis | 4 | 2020 | 2593 | 0.620 |
Why?
|
Hypocalcemia | 1 | 2019 | 191 | 0.600 |
Why?
|
Kidney Diseases | 2 | 2024 | 2149 | 0.600 |
Why?
|
Glucuronidase | 1 | 2019 | 207 | 0.600 |
Why?
|
Minerals | 1 | 2019 | 275 | 0.600 |
Why?
|
Hyperphosphatemia | 2 | 2019 | 40 | 0.590 |
Why?
|
Mesothelioma | 1 | 2023 | 818 | 0.590 |
Why?
|
Humans | 126 | 2024 | 744343 | 0.570 |
Why?
|
Cation Exchange Resins | 1 | 2016 | 21 | 0.570 |
Why?
|
Causality | 1 | 2022 | 1275 | 0.550 |
Why?
|
Vitamin D Deficiency | 2 | 2019 | 1343 | 0.550 |
Why?
|
Polystyrenes | 1 | 2016 | 112 | 0.540 |
Why?
|
Cholecalciferol | 1 | 2021 | 537 | 0.540 |
Why?
|
Antimicrobial Cationic Peptides | 2 | 2015 | 362 | 0.540 |
Why?
|
Creatinine | 7 | 2024 | 1919 | 0.520 |
Why?
|
Tissue Plasminogen Activator | 1 | 2021 | 1261 | 0.510 |
Why?
|
Organ Transplantation | 2 | 2021 | 1139 | 0.460 |
Why?
|
Heme Oxygenase-1 | 1 | 2016 | 381 | 0.460 |
Why?
|
24,25-Dihydroxyvitamin D 3 | 1 | 2013 | 9 | 0.460 |
Why?
|
Kidney Glomerulus | 2 | 2020 | 697 | 0.450 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2021 | 980 | 0.450 |
Why?
|
Osteomalacia | 1 | 2013 | 53 | 0.440 |
Why?
|
Glomerular Filtration Rate | 7 | 2023 | 2170 | 0.440 |
Why?
|
Middle Aged | 60 | 2024 | 213383 | 0.430 |
Why?
|
Fluorobenzenes | 1 | 2014 | 183 | 0.430 |
Why?
|
Hydrocephalus, Normal Pressure | 1 | 2013 | 92 | 0.430 |
Why?
|
Lateral Ventricles | 1 | 2013 | 146 | 0.420 |
Why?
|
Vitamin D-Binding Protein | 1 | 2013 | 129 | 0.420 |
Why?
|
Postoperative Complications | 6 | 2020 | 15295 | 0.410 |
Why?
|
Parathyroid Hormone | 6 | 2019 | 1801 | 0.410 |
Why?
|
Unnecessary Procedures | 1 | 2016 | 432 | 0.410 |
Why?
|
Aged | 53 | 2023 | 163280 | 0.410 |
Why?
|
Laxatives | 1 | 2012 | 87 | 0.400 |
Why?
|
Ergocalciferols | 1 | 2012 | 110 | 0.390 |
Why?
|
Kidney Function Tests | 4 | 2020 | 684 | 0.390 |
Why?
|
Hypercalciuria | 1 | 2010 | 31 | 0.390 |
Why?
|
Female | 73 | 2023 | 380194 | 0.390 |
Why?
|
Cefoxitin | 1 | 2010 | 36 | 0.380 |
Why?
|
Kidney Transplantation | 3 | 2021 | 4251 | 0.380 |
Why?
|
Nephrolithiasis | 1 | 2012 | 110 | 0.380 |
Why?
|
Male | 71 | 2023 | 350118 | 0.370 |
Why?
|
Medical Order Entry Systems | 1 | 2016 | 545 | 0.370 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2023 | 5442 | 0.370 |
Why?
|
Cerebral Ventricles | 1 | 2013 | 544 | 0.370 |
Why?
|
Drug Monitoring | 1 | 2016 | 956 | 0.360 |
Why?
|
Anemia, Hemolytic | 1 | 2010 | 168 | 0.350 |
Why?
|
Nurse-Patient Relations | 1 | 2010 | 101 | 0.350 |
Why?
|
Facility Design and Construction | 1 | 2010 | 87 | 0.340 |
Why?
|
Urokinase-Type Plasminogen Activator | 2 | 2020 | 336 | 0.330 |
Why?
|
Rhabdomyolysis | 1 | 2009 | 150 | 0.330 |
Why?
|
Neoplasms | 4 | 2024 | 21683 | 0.320 |
Why?
|
Respiratory Insufficiency | 3 | 2021 | 1199 | 0.320 |
Why?
|
Sinoatrial Node | 1 | 2008 | 101 | 0.320 |
Why?
|
Immunotherapy | 3 | 2021 | 4445 | 0.310 |
Why?
|
Immunologic Factors | 2 | 2017 | 1580 | 0.310 |
Why?
|
Risk Factors | 22 | 2024 | 72290 | 0.300 |
Why?
|
Standard of Care | 2 | 2021 | 564 | 0.300 |
Why?
|
Research Design | 1 | 2022 | 5987 | 0.290 |
Why?
|
Pregnancy Complications | 1 | 2021 | 2861 | 0.280 |
Why?
|
Hydrocephalus | 1 | 2013 | 748 | 0.280 |
Why?
|
Acetazolamide | 1 | 2006 | 100 | 0.280 |
Why?
|
Connexins | 1 | 2008 | 357 | 0.280 |
Why?
|
Carbonic Anhydrase Inhibitors | 1 | 2006 | 95 | 0.280 |
Why?
|
Adult | 38 | 2024 | 214055 | 0.270 |
Why?
|
Altitude Sickness | 1 | 2006 | 92 | 0.270 |
Why?
|
Polymorphism, Genetic | 1 | 2016 | 4328 | 0.260 |
Why?
|
Sulfonamides | 1 | 2014 | 1938 | 0.250 |
Why?
|
Cathelicidins | 2 | 2015 | 80 | 0.250 |
Why?
|
Cohort Studies | 19 | 2024 | 40561 | 0.250 |
Why?
|
Retrospective Studies | 22 | 2024 | 77449 | 0.240 |
Why?
|
Anemia, Iron-Deficiency | 2 | 2019 | 365 | 0.240 |
Why?
|
Ferritins | 2 | 2019 | 590 | 0.240 |
Why?
|
Renal Dialysis | 4 | 2023 | 1786 | 0.240 |
Why?
|
Risk Assessment | 5 | 2024 | 23338 | 0.240 |
Why?
|
Brain Diseases | 1 | 2013 | 1563 | 0.230 |
Why?
|
Prone Position | 2 | 2021 | 194 | 0.230 |
Why?
|
Receptors, Urokinase Plasminogen Activator | 2 | 2020 | 90 | 0.220 |
Why?
|
Calcium | 2 | 2017 | 5756 | 0.220 |
Why?
|
Clinical Trials as Topic | 2 | 2016 | 7913 | 0.220 |
Why?
|
Receptors, Interleukin-6 | 2 | 2021 | 224 | 0.220 |
Why?
|
Incidence | 9 | 2021 | 20947 | 0.210 |
Why?
|
Hemochromatosis | 1 | 2023 | 184 | 0.210 |
Why?
|
Pyrimidines | 1 | 2014 | 2942 | 0.210 |
Why?
|
Oxygen | 2 | 2021 | 4189 | 0.210 |
Why?
|
Phosphates | 3 | 2016 | 786 | 0.210 |
Why?
|
Transferrin | 2 | 2023 | 295 | 0.210 |
Why?
|
Educational Measurement | 1 | 2009 | 1210 | 0.210 |
Why?
|
Fibrin Fibrinogen Degradation Products | 2 | 2021 | 426 | 0.210 |
Why?
|
Bilirubin | 1 | 2023 | 425 | 0.200 |
Why?
|
Iron Overload | 1 | 2023 | 242 | 0.200 |
Why?
|
Prospective Studies | 11 | 2020 | 53288 | 0.200 |
Why?
|
Patient Positioning | 2 | 2021 | 324 | 0.200 |
Why?
|
Bradycardia | 1 | 2023 | 307 | 0.200 |
Why?
|
Kidney Tubules | 2 | 2020 | 488 | 0.200 |
Why?
|
Immunotherapy, Adoptive | 2 | 2020 | 1270 | 0.200 |
Why?
|
Kidney Failure, Chronic | 2 | 2017 | 2538 | 0.190 |
Why?
|
Pandemics | 7 | 2022 | 8388 | 0.190 |
Why?
|
Colonic Neoplasms | 1 | 2013 | 2541 | 0.190 |
Why?
|
Antineoplastic Agents | 3 | 2023 | 13695 | 0.190 |
Why?
|
Heart Arrest | 2 | 2021 | 1470 | 0.190 |
Why?
|
Treatment Outcome | 11 | 2023 | 63114 | 0.190 |
Why?
|
United States | 19 | 2022 | 69872 | 0.190 |
Why?
|
Dexamethasone | 2 | 2020 | 1951 | 0.190 |
Why?
|
Program Evaluation | 1 | 2009 | 2488 | 0.180 |
Why?
|
Antiviral Agents | 2 | 2023 | 2987 | 0.180 |
Why?
|
Glycerophosphates | 1 | 2020 | 48 | 0.180 |
Why?
|
Medical Futility | 1 | 2021 | 127 | 0.180 |
Why?
|
Antibodies, Monoclonal | 2 | 2020 | 9274 | 0.180 |
Why?
|
Magnesium | 1 | 2023 | 813 | 0.180 |
Why?
|
Iatrogenic Disease | 1 | 2023 | 547 | 0.180 |
Why?
|
Education, Medical, Undergraduate | 1 | 2009 | 1008 | 0.180 |
Why?
|
Oxygen Consumption | 1 | 2006 | 1869 | 0.180 |
Why?
|
Hemorrhage | 3 | 2021 | 3461 | 0.180 |
Why?
|
Retroperitoneal Space | 1 | 2020 | 176 | 0.170 |
Why?
|
Aged, 80 and over | 13 | 2021 | 57776 | 0.170 |
Why?
|
Severity of Illness Index | 7 | 2021 | 15540 | 0.170 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 3255 | 0.170 |
Why?
|
Prednisone | 2 | 2017 | 1574 | 0.170 |
Why?
|
Intraoperative Care | 2 | 2021 | 767 | 0.170 |
Why?
|
Resuscitation Orders | 1 | 2021 | 269 | 0.170 |
Why?
|
Length of Stay | 5 | 2021 | 6309 | 0.170 |
Why?
|
Water-Electrolyte Imbalance | 1 | 2020 | 113 | 0.170 |
Why?
|
Anemia | 1 | 2008 | 1506 | 0.170 |
Why?
|
Sodium | 2 | 2016 | 1623 | 0.160 |
Why?
|
Renin-Angiotensin System | 1 | 2023 | 759 | 0.160 |
Why?
|
Arrhythmias, Cardiac | 1 | 2008 | 2268 | 0.160 |
Why?
|
Glucocorticoids | 2 | 2019 | 2107 | 0.160 |
Why?
|
Health Care Rationing | 1 | 2021 | 437 | 0.160 |
Why?
|
Comorbidity | 6 | 2021 | 10388 | 0.160 |
Why?
|
Oxygen Inhalation Therapy | 1 | 2021 | 367 | 0.150 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2019 | 9959 | 0.150 |
Why?
|
Vomiting | 1 | 2021 | 636 | 0.150 |
Why?
|
Blood Coagulation Disorders | 1 | 2021 | 337 | 0.150 |
Why?
|
Students, Dental | 1 | 2019 | 160 | 0.150 |
Why?
|
Biosynthetic Pathways | 1 | 2018 | 137 | 0.150 |
Why?
|
Comparative Effectiveness Research | 1 | 2022 | 681 | 0.150 |
Why?
|
Interferon Regulatory Factor-2 | 1 | 2017 | 23 | 0.150 |
Why?
|
Pilot Projects | 3 | 2023 | 8324 | 0.150 |
Why?
|
Salivary Proteins and Peptides | 1 | 2017 | 53 | 0.150 |
Why?
|
Hyperparathyroidism | 1 | 2019 | 339 | 0.150 |
Why?
|
Patients | 1 | 2024 | 900 | 0.150 |
Why?
|
Hospitals | 2 | 2021 | 3952 | 0.150 |
Why?
|
Glomerulosclerosis, Focal Segmental | 1 | 2020 | 357 | 0.150 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2023 | 924 | 0.150 |
Why?
|
Natural Killer T-Cells | 1 | 2020 | 316 | 0.140 |
Why?
|
Thrombosis | 2 | 2021 | 2968 | 0.140 |
Why?
|
Internet | 1 | 2009 | 3064 | 0.140 |
Why?
|
Blood Protein Electrophoresis | 1 | 2016 | 73 | 0.140 |
Why?
|
Respiration, Artificial | 3 | 2023 | 2569 | 0.140 |
Why?
|
Heparin | 1 | 2023 | 1637 | 0.140 |
Why?
|
Cryoglobulins | 1 | 2016 | 59 | 0.140 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2023 | 1518 | 0.140 |
Why?
|
Prognosis | 5 | 2021 | 29063 | 0.140 |
Why?
|
Hepatitis E | 1 | 2017 | 76 | 0.140 |
Why?
|
Arteriosclerosis | 1 | 2020 | 1092 | 0.140 |
Why?
|
Glomerulonephritis, Membranous | 1 | 2017 | 86 | 0.130 |
Why?
|
Substance-Related Disorders | 1 | 2012 | 4258 | 0.130 |
Why?
|
Transplantation Conditioning | 2 | 2023 | 1598 | 0.130 |
Why?
|
Fibrosis | 2 | 2020 | 2029 | 0.130 |
Why?
|
Antibodies | 1 | 2023 | 2460 | 0.130 |
Why?
|
Complement C4 | 1 | 2016 | 257 | 0.130 |
Why?
|
Myocardium | 1 | 2008 | 4776 | 0.130 |
Why?
|
Adenocarcinoma | 1 | 2013 | 6364 | 0.130 |
Why?
|
Pleural Neoplasms | 1 | 2020 | 607 | 0.130 |
Why?
|
Triage | 1 | 2021 | 976 | 0.120 |
Why?
|
Apolipoproteins | 1 | 2017 | 317 | 0.120 |
Why?
|
Erythropoietin | 1 | 2019 | 726 | 0.120 |
Why?
|
Nephrectomy | 1 | 2020 | 1050 | 0.120 |
Why?
|
Logistic Models | 4 | 2020 | 13408 | 0.120 |
Why?
|
NAD | 1 | 2018 | 593 | 0.120 |
Why?
|
Erythrocyte Transfusion | 2 | 2021 | 565 | 0.120 |
Why?
|
Multivariate Analysis | 3 | 2013 | 12245 | 0.120 |
Why?
|
Blood Coagulation | 1 | 2020 | 1127 | 0.120 |
Why?
|
T-Box Domain Proteins | 1 | 2017 | 471 | 0.120 |
Why?
|
Kidney Neoplasms | 2 | 2021 | 4262 | 0.120 |
Why?
|
Urine | 1 | 2016 | 370 | 0.120 |
Why?
|
Acid-Base Equilibrium | 1 | 2015 | 185 | 0.120 |
Why?
|
Hospital Design and Construction | 1 | 2014 | 33 | 0.120 |
Why?
|
Biopsy | 2 | 2016 | 6756 | 0.120 |
Why?
|
Lipocalins | 1 | 2015 | 170 | 0.120 |
Why?
|
Complement C3 | 1 | 2016 | 461 | 0.120 |
Why?
|
Antibodies, Antineutrophil Cytoplasmic | 1 | 2016 | 288 | 0.120 |
Why?
|
Patients' Rooms | 1 | 2014 | 63 | 0.120 |
Why?
|
Acute-Phase Proteins | 1 | 2015 | 262 | 0.120 |
Why?
|
Urea | 1 | 2016 | 450 | 0.110 |
Why?
|
Urinalysis | 1 | 2016 | 369 | 0.110 |
Why?
|
APACHE | 2 | 2014 | 277 | 0.110 |
Why?
|
Erythropoiesis | 1 | 2017 | 705 | 0.110 |
Why?
|
Blood Loss, Surgical | 1 | 2017 | 662 | 0.110 |
Why?
|
Survival Rate | 5 | 2021 | 12788 | 0.110 |
Why?
|
Proteinuria | 1 | 2016 | 658 | 0.110 |
Why?
|
Catalysis | 1 | 2014 | 761 | 0.110 |
Why?
|
Time Factors | 6 | 2017 | 40075 | 0.110 |
Why?
|
Algorithms | 3 | 2021 | 13881 | 0.110 |
Why?
|
Animals | 12 | 2020 | 168757 | 0.110 |
Why?
|
Lipoproteins, HDL | 1 | 2017 | 638 | 0.110 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3133 | 0.110 |
Why?
|
Anti-Bacterial Agents | 1 | 2010 | 7181 | 0.110 |
Why?
|
Hypophosphatemia | 1 | 2013 | 85 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3240 | 0.100 |
Why?
|
Injections, Intravenous | 1 | 2014 | 1420 | 0.100 |
Why?
|
Hospitalization | 6 | 2023 | 10262 | 0.100 |
Why?
|
Autoantibodies | 2 | 2021 | 2035 | 0.100 |
Why?
|
Cell Count | 1 | 2016 | 1856 | 0.100 |
Why?
|
Interferon-gamma | 1 | 2020 | 3206 | 0.100 |
Why?
|
Paraneoplastic Syndromes | 1 | 2013 | 151 | 0.100 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2020 | 2540 | 0.100 |
Why?
|
Case-Control Studies | 5 | 2017 | 21746 | 0.100 |
Why?
|
Proto-Oncogene Proteins | 2 | 2015 | 4554 | 0.100 |
Why?
|
Immune Tolerance | 1 | 2020 | 2258 | 0.100 |
Why?
|
Killer Cells, Natural | 1 | 2020 | 2133 | 0.100 |
Why?
|
Eosinophils | 1 | 2016 | 955 | 0.100 |
Why?
|
Cyclophosphamide | 1 | 2017 | 2242 | 0.100 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2020 | 2109 | 0.090 |
Why?
|
Menorrhagia | 1 | 2010 | 63 | 0.090 |
Why?
|
Statistics, Nonparametric | 2 | 2017 | 2886 | 0.090 |
Why?
|
Graft vs Host Disease | 1 | 2023 | 2957 | 0.090 |
Why?
|
Signal Transduction | 3 | 2020 | 23403 | 0.090 |
Why?
|
25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2009 | 61 | 0.090 |
Why?
|
New York City | 1 | 2012 | 710 | 0.090 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2021 | 1354 | 0.090 |
Why?
|
Patient Selection | 2 | 2019 | 4215 | 0.090 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2020 | 1378 | 0.090 |
Why?
|
Drug Utilization | 1 | 2016 | 1183 | 0.090 |
Why?
|
Postoperative Period | 1 | 2015 | 1842 | 0.090 |
Why?
|
Carcinoma, Renal Cell | 2 | 2021 | 3143 | 0.090 |
Why?
|
Diagnostic Tests, Routine | 1 | 2015 | 783 | 0.080 |
Why?
|
Anti-Inflammatory Agents | 2 | 2017 | 1790 | 0.080 |
Why?
|
Anticoagulants | 2 | 2021 | 4599 | 0.080 |
Why?
|
Hospitals, General | 1 | 2013 | 749 | 0.080 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2021 | 2245 | 0.080 |
Why?
|
Disease Management | 2 | 2016 | 2459 | 0.080 |
Why?
|
Follow-Up Studies | 5 | 2021 | 39050 | 0.080 |
Why?
|
Odds Ratio | 3 | 2020 | 9849 | 0.080 |
Why?
|
Population Surveillance | 1 | 2019 | 2616 | 0.080 |
Why?
|
Adrenal Cortex Hormones | 3 | 2022 | 1855 | 0.080 |
Why?
|
Glomerulonephritis | 1 | 2010 | 372 | 0.080 |
Why?
|
Microscopy, Video | 1 | 2008 | 245 | 0.080 |
Why?
|
Cerebral Hemorrhage | 1 | 2019 | 2647 | 0.080 |
Why?
|
Coronary Angiography | 1 | 2020 | 4577 | 0.080 |
Why?
|
Sex Factors | 1 | 2021 | 10397 | 0.080 |
Why?
|
Shock, Septic | 1 | 2014 | 775 | 0.080 |
Why?
|
Ventilators, Mechanical | 1 | 2010 | 292 | 0.080 |
Why?
|
ras Proteins | 1 | 2013 | 1060 | 0.080 |
Why?
|
Practice Guidelines as Topic | 2 | 2021 | 7279 | 0.080 |
Why?
|
Connexin 43 | 1 | 2008 | 207 | 0.070 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2023 | 3523 | 0.070 |
Why?
|
Checklist | 1 | 2014 | 833 | 0.070 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2011 | 501 | 0.070 |
Why?
|
Quality of Life | 1 | 2008 | 12804 | 0.070 |
Why?
|
Medical Staff, Hospital | 1 | 2011 | 603 | 0.070 |
Why?
|
New York | 1 | 2009 | 886 | 0.070 |
Why?
|
Students, Medical | 1 | 2019 | 1862 | 0.070 |
Why?
|
Microscopy, Fluorescence | 2 | 2017 | 2699 | 0.070 |
Why?
|
Age of Onset | 1 | 2013 | 3271 | 0.070 |
Why?
|
Drug Administration Schedule | 1 | 2014 | 4933 | 0.070 |
Why?
|
Acute Coronary Syndrome | 1 | 2019 | 2337 | 0.070 |
Why?
|
Adolescent | 6 | 2021 | 85781 | 0.070 |
Why?
|
Reference Values | 1 | 2013 | 4982 | 0.070 |
Why?
|
Hematinics | 1 | 2008 | 281 | 0.070 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 1692 | 0.070 |
Why?
|
Resuscitation | 1 | 2010 | 658 | 0.060 |
Why?
|
Double-Blind Method | 2 | 2021 | 12026 | 0.060 |
Why?
|
Leiomyoma | 1 | 2010 | 730 | 0.060 |
Why?
|
Predictive Value of Tests | 2 | 2018 | 15076 | 0.060 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2020 | 4034 | 0.060 |
Why?
|
Atrial Appendage | 1 | 2008 | 283 | 0.060 |
Why?
|
Cardiac Pacing, Artificial | 1 | 2008 | 845 | 0.060 |
Why?
|
Stroke Volume | 1 | 2017 | 5007 | 0.060 |
Why?
|
Mice, Knockout | 3 | 2020 | 14557 | 0.060 |
Why?
|
Blood Transfusion | 1 | 2010 | 1301 | 0.060 |
Why?
|
Guideline Adherence | 1 | 2014 | 2266 | 0.060 |
Why?
|
Veterans | 1 | 2017 | 2519 | 0.060 |
Why?
|
Disease Models, Animal | 3 | 2020 | 18029 | 0.060 |
Why?
|
Massachusetts | 1 | 2016 | 8663 | 0.060 |
Why?
|
Up-Regulation | 1 | 2012 | 4217 | 0.050 |
Why?
|
Baclofen | 1 | 2023 | 129 | 0.050 |
Why?
|
Ultrasonography | 1 | 2016 | 5985 | 0.050 |
Why?
|
Immunity, Innate | 1 | 2014 | 2958 | 0.050 |
Why?
|
Digoxin | 1 | 2023 | 250 | 0.050 |
Why?
|
Cystatin C | 1 | 2023 | 250 | 0.050 |
Why?
|
Boston | 1 | 2015 | 9313 | 0.050 |
Why?
|
Membrane Proteins | 1 | 2019 | 7880 | 0.050 |
Why?
|
Linear Models | 1 | 2012 | 5952 | 0.050 |
Why?
|
Inflammation | 1 | 2021 | 10638 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 2020 | 5686 | 0.050 |
Why?
|
Mice | 7 | 2020 | 81183 | 0.050 |
Why?
|
Young Adult | 5 | 2021 | 56430 | 0.050 |
Why?
|
Consensus | 1 | 2010 | 2959 | 0.050 |
Why?
|
Quality Improvement | 1 | 2016 | 3749 | 0.050 |
Why?
|
Action Potentials | 1 | 2008 | 1806 | 0.050 |
Why?
|
Kinetics | 1 | 2008 | 6473 | 0.050 |
Why?
|
Sclerosis | 1 | 2020 | 213 | 0.050 |
Why?
|
Receptors, Lysophosphatidic Acid | 1 | 2020 | 76 | 0.040 |
Why?
|
Vancomycin | 1 | 2023 | 501 | 0.040 |
Why?
|
Receptors, Chemokine | 1 | 2023 | 669 | 0.040 |
Why?
|
Adaptation, Physiological | 1 | 2006 | 1312 | 0.040 |
Why?
|
Proportional Hazards Models | 3 | 2021 | 12354 | 0.040 |
Why?
|
Antigens, CD1d | 1 | 2020 | 220 | 0.040 |
Why?
|
Mycophenolic Acid | 1 | 2021 | 343 | 0.040 |
Why?
|
Cytokines | 1 | 2014 | 7322 | 0.040 |
Why?
|
Candida | 1 | 2020 | 172 | 0.040 |
Why?
|
Time | 1 | 2021 | 542 | 0.040 |
Why?
|
Obesity | 1 | 2021 | 12745 | 0.040 |
Why?
|
Pregnancy | 1 | 2021 | 29144 | 0.040 |
Why?
|
Prevalence | 2 | 2019 | 15226 | 0.040 |
Why?
|
Pentosyltransferases | 1 | 2018 | 65 | 0.040 |
Why?
|
Quinolinic Acid | 1 | 2018 | 67 | 0.040 |
Why?
|
Water-Electrolyte Balance | 1 | 2020 | 346 | 0.040 |
Why?
|
Mortality | 2 | 2021 | 2864 | 0.040 |
Why?
|
Thrombophilia | 1 | 2021 | 305 | 0.040 |
Why?
|
Troponin I | 1 | 2022 | 619 | 0.040 |
Why?
|
Immunoglobulins | 1 | 2021 | 881 | 0.040 |
Why?
|
Dietary Supplements | 1 | 2010 | 3297 | 0.040 |
Why?
|
Primary Health Care | 1 | 2014 | 4558 | 0.040 |
Why?
|
Age Factors | 2 | 2020 | 18370 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2022 | 13102 | 0.040 |
Why?
|
Genome-Wide Association Study | 1 | 2017 | 12261 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2013 | 12959 | 0.040 |
Why?
|
Platelet Count | 1 | 2020 | 781 | 0.040 |
Why?
|
Candidiasis | 1 | 2020 | 366 | 0.040 |
Why?
|
Liposarcoma | 1 | 2020 | 333 | 0.040 |
Why?
|
Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2017 | 70 | 0.040 |
Why?
|
Medical Records, Problem-Oriented | 1 | 2016 | 35 | 0.040 |
Why?
|
Survival Analysis | 2 | 2021 | 10252 | 0.040 |
Why?
|
Hyperthermia, Induced | 1 | 2020 | 403 | 0.040 |
Why?
|
Cardiovascular Diseases | 1 | 2022 | 15165 | 0.040 |
Why?
|
Parotid Gland | 1 | 2017 | 168 | 0.040 |
Why?
|
Tryptophan | 1 | 2018 | 478 | 0.030 |
Why?
|
Niacinamide | 1 | 2018 | 417 | 0.030 |
Why?
|
Leiomyosarcoma | 1 | 2020 | 477 | 0.030 |
Why?
|
Atrophy | 1 | 2020 | 1583 | 0.030 |
Why?
|
Podocytes | 1 | 2020 | 396 | 0.030 |
Why?
|
Aftercare | 1 | 2021 | 866 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2017 | 17446 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2309 | 0.030 |
Why?
|
Heart | 1 | 2008 | 4467 | 0.030 |
Why?
|
Electrocardiography | 1 | 2008 | 6442 | 0.030 |
Why?
|
Proton Pump Inhibitors | 1 | 2019 | 526 | 0.030 |
Why?
|
Netherlands | 1 | 2019 | 2170 | 0.030 |
Why?
|
Protein Folding | 1 | 2017 | 843 | 0.030 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2020 | 808 | 0.030 |
Why?
|
Pneumonectomy | 1 | 2020 | 1094 | 0.030 |
Why?
|
Geriatric Assessment | 1 | 2021 | 1372 | 0.030 |
Why?
|
Saliva | 1 | 2017 | 809 | 0.030 |
Why?
|
Heart Failure | 1 | 2017 | 10900 | 0.030 |
Why?
|
RNA, Messenger | 1 | 2008 | 13033 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2021 | 13989 | 0.030 |
Why?
|
United States Department of Veterans Affairs | 1 | 2017 | 875 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 20129 | 0.030 |
Why?
|
Drug Combinations | 1 | 2017 | 1959 | 0.020 |
Why?
|
Metabolomics | 1 | 2020 | 1484 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2017 | 2559 | 0.020 |
Why?
|
HIV Infections | 1 | 2017 | 16718 | 0.020 |
Why?
|
Cause of Death | 1 | 2021 | 3584 | 0.020 |
Why?
|
Reperfusion Injury | 1 | 2017 | 1026 | 0.020 |
Why?
|
Mice, Inbred Strains | 1 | 2013 | 1827 | 0.020 |
Why?
|
Risk Reduction Behavior | 1 | 2017 | 1125 | 0.020 |
Why?
|
Disease Progression | 2 | 2017 | 13284 | 0.020 |
Why?
|
Outpatients | 1 | 2017 | 1486 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2021 | 4560 | 0.020 |
Why?
|
Ischemia | 1 | 2018 | 1907 | 0.020 |
Why?
|
Aging | 1 | 2008 | 8664 | 0.020 |
Why?
|
Administration, Oral | 1 | 2017 | 3913 | 0.020 |
Why?
|
Patient Discharge | 1 | 2021 | 3313 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3778 | 0.020 |
Why?
|
Physician Assistants | 1 | 2011 | 193 | 0.020 |
Why?
|
Venous Thromboembolism | 1 | 2021 | 1671 | 0.020 |
Why?
|
Viral Load | 1 | 2017 | 3299 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2020 | 8642 | 0.020 |
Why?
|
Data Collection | 1 | 2017 | 3341 | 0.020 |
Why?
|
Nurse Practitioners | 1 | 2011 | 270 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2017 | 21827 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2020 | 9734 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2017 | 6489 | 0.020 |
Why?
|
Homeostasis | 1 | 2017 | 3340 | 0.020 |
Why?
|
Folic Acid | 1 | 2013 | 1300 | 0.020 |
Why?
|
Acute Disease | 1 | 2017 | 7149 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2017 | 5867 | 0.020 |
Why?
|
Cell Line | 1 | 2020 | 15997 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 10943 | 0.020 |
Why?
|
Proteomics | 1 | 2017 | 3638 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2017 | 4149 | 0.010 |
Why?
|
Computer Simulation | 1 | 2017 | 6196 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5391 | 0.010 |
Why?
|
Genotype | 1 | 2017 | 12951 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 11524 | 0.010 |
Why?
|
Anti-HIV Agents | 1 | 2017 | 4256 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2017 | 9438 | 0.010 |
Why?
|
Models, Biological | 1 | 2017 | 9583 | 0.010 |
Why?
|
Body Mass Index | 1 | 2017 | 12720 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2020 | 25043 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2017 | 12072 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2017 | 15519 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2015 | 19905 | 0.010 |
Why?
|
Internship and Residency | 1 | 2011 | 5788 | 0.010 |
Why?
|